3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
CNS
2
Conditions
Glioblastoma
4
Multiple Myeloma
2
Lymphoma
2
Glioma
2
Whooping Cough
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumococcal Infections
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Measles
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Human Papillomavirus-Related Cervical Carcinoma
1
Hodgkin Disease
1
Hepatitis B
1
HIV Infections
1
Gliosarcoma
1
Interventions
Temozolomide
156
Bevacizumab
69
Radiotherapy
61
Magnetic Resonance Spectroscopy
59
Irinotecan
31
Surgical Procedures, Operative
23
Radiation
23
Carboplatin
23
Specimen Handling
20
Carmustine
20
Nivolumab
19
Biopsy
17
Lomustine
16
Aminolevulinic Acid
15
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
trametinib
12
pembrolizumab
12
Radiosurgery
12
Erlotinib Hydrochloride
12
fluorodopa F 18
11
Topotecan
11
Everolimus
11
Blood Specimen Collection
11
X-Rays
10
IL13-PE38
10
dabrafenib
9
Etoposide
9
ribociclib
8
poly ICLC
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Glioma
×
Tetanus Toxoid
×
Clear all
NCT02465268
2025-01-14
ATTAC-II
University of Florida
Phase 2
Completed
175 enrolled
18 charts
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts